N-ras gene point mutations in childhood acute lymphocytic leukemia correlate with a poor prognosis.
Ras genes can be altered by point mutations at critical portions of their coding regions to acquire transforming ability in vitro. These point mutations have been detected in a variety of human malignancies. However, their relevance for the clinical and biologic behavior of the subgroups of patients exhibiting these mutations in unclear. We analyzed 100 patients with childhood acute lymphocytic leukemias (ALLs) for point mutations of exons 1 and 2 of all three ras genes (H-ras, K-ras, and N-ras) by polymerase chain reaction and a combination of oligonucleotide hybridization and direct DNA sequencing. A 6% incidence of N-ras gene mutations was detected, all of which occurred at different nucleotides of codons 12 or 13 of N-ras. When correlating presence of ras mutations with the clinical and biologic features and the clinical outcome of these cases, a significantly higher risk for hematologic relapse (P = .01) and a trend toward a lower rate of complete remission (P = .07) was noted. The two groups did not differ in any of the known high-risk factors of ALL. These results suggest that presence of an N-ras mutation in children with ALL may be an independent predictor for worse clinical outcome and therefore may have therapeutic implications; further studies to confirm these findings are required because of the small number of patients with N-ras mutations.
UCLA Department of Medicine.
M
M
Lübbert
J
J
Mirro
C W
CW
Miller
J
J
Kahan
G
G
Isaac
G
G
Kitchingman
R
R
Mertelsmann
F
F
Herrmann
F
F
McCormick
H P
HP
Koeffler
D015703:Antigens, CD / Q000032:analysis; D001483:Base Sequence; D002454:Cell Differentiation; D002648:Child; D002675:Child, Preschool; D005787:Gene Frequency; D011905:Genes, ras; D006801:Humans; D007223:Infant; D008969:Molecular Sequence Data; D009154:Mutation; D016133:Polymerase Chain Reaction; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000175:diagnosis / Q000235:genetics* / Q000276:immunology; D011379:Prognosis; D016019:Survival Analysis
D015703:Antigens, CD